Genetic Testing Cost, Explained: From Scope to Insurance

Genetic testing cost ranges widely. For example, a test that looks at a single gene costs less than reading all protein-coding genes at once. But the clinically useful question is rarely “what is the cheapest test” — it is “which test is most likely to give an answer, and what does that answer save downstream.”

Frequently asked questions

How much does genetic testing cost?

It depends on scope. Single-gene tests are the least expensive, multi-gene panels fall in the middle, and whole exome or genome sequencing are the most comprehensive and typically the most expensive. Insurance coverage can substantially change the out-of-pocket amount.

Why is whole exome sequencing more expensive than a panel?

Whole exome sequencing reads all protein-coding genes rather than a selected subset, generating far more data to process, interpret, and clinically classify. That breadth raises cost but also raises the chance of finding an unexpected diagnosis.

Is broad genetic testing worth the higher price?

It can be. In rare disease, broad sequencing may shorten the diagnostic journey and avoid the repeated inconclusive tests, procedures, and specialist visits that add up over years — though this depends on the condition, the health system, and when the test is used.

Does testing family members increase the cost?

Testing parents or siblings alongside the patient — a trio approach — adds to the upfront cost but frequently speeds interpretation. Comparing a child’s variants to parents helps distinguish meaningful findings from harmless ones.

Does insurance cover genetic testing?

Coverage varies by payer, region, and clinical indication. Many plans cover testing when there is a documented medical reason and clear criteria are met. Confirm specifics with the laboratory and a genetic counselor before ordering.

---

What Drives Genetic Testing Cost

Three factors shape most of the cost of genetic testing.

• Scope of the test — how much of the genome is examined, from one gene to all of them.
• Interpretation — the human and computational work of classifying variants against databases and guidelines.
• Who is tested — testing a patient alone versus testing a family group.

Sequencing chemistry has become dramatically cheaper over the past two decades, so raw data generation is no longer the main expense. Interpretation — deciding whether a variant explains the phenotype — now carries much of the clinical value and much of the cost.

Test types, from narrow to broad

A single-gene test suits cases with a strong, specific clinical suspicion. A gene panel examines a curated set of genes tied to one condition or symptom group. Whole exome sequencing reads the roughly 1–2% of the genome that codes for proteins, where most known disease-causing variants sit. Whole genome sequencing reads nearly the entire genome.

As scope widens, so does both price and diagnostic reach. The trade-off is not just money — broader tests also raise the chance of findings that are uncertain or unrelated to the original question.

Cost versus value in rare disease

The headline price understates what a diagnosis is worth to a family facing a rare disease. Many patients spend years moving between hospitals and inconclusive tests — the so-called diagnostic odyssey. Each step carries its own cost.

The key question is whether to repeat narrow tests over time or to go broad early. A diagnostic and health-economic analysis of whole exome and genome sequencing in Mendelian disorders shows that diagnostic yield and cost should be weighed together, not price in isolation. The evidence is not settled in one direction, however: a systematic review of economic evaluations of whole genome and exome sequencing pooled the available studies and concluded that the economic evidence is still limited and that more rigorous evaluation is needed.

Context matters. A study of massively parallel sequencing for paediatric muscle diseases found favorable cost-effectiveness in that rare disease setting, and a separate analysis of targeted exome analysis in glomerular kidney diseases reached a similar conclusion in children with that condition group.

When in the workup you test matters

Rather than repeating narrow tests over time, using broad sequencing early may help lower total cost by ending the search sooner. An analysis asking whether when in the diagnostic pathway exome sequencing is performed affects its cost-effectiveness examined exactly this question in children with suspected monogenic conditions.

Work in previously undiagnosed children supports the same idea. A study of the cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions compared the costs and diagnostic outcomes of several testing strategies.

Before you order: points to consider

• Confirm current pricing and coverage criteria directly with the laboratory before ordering.
• Consider whether trio testing (patient plus parents) will speed interpretation enough to justify the added cost.
• Factor in the costs already spent on an inconclusive workup — broad testing may be cheaper than continuing piecemeal.
• Involve a genetic counselor early to match test scope to the clinical question and to prepare patients and families for possible uncertain findings.

* Many of the studies cited above were conducted in Australia, the UK, and the US, and may not represent the situation in every country.

References

1. Ewans LJ, Minoche AE, Schofield D, et al. Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis. Eur J Hum Genet. 2022;30(10):1121-1131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553973/
2. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20(10):1122-1130. https://pubmed.ncbi.nlm.nih.gov/29446766/
3. Schofield D, Alam K, Douglas L, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. NPJ Genom Med. 2017;2:4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677979/
4. Jayasinghe K, Wu Y, Stark Z, et al. Cost-effectiveness of targeted exome analysis as a diagnostic test in glomerular diseases. Kidney Int Rep. 2021;6(11):2850-2861. https://pmc.ncbi.nlm.nih.gov/articles/PMC8589690/
5. Tan TY, Dillon OJ, Stark Z, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171(9):855-862. https://pubmed.ncbi.nlm.nih.gov/28759686/
6. Lavelle TA, Feng X, Keisler M, et al. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genet Med. 2022;24(6):1349-1361. https://pubmed.ncbi.nlm.nih.gov/35396982/